Chemicals

Amyris to buy Oobli, adding fermentation-made sweet proteins to its portfolio

The biomanufacturing company pairs its strain engineering and fermentation scale with Oobli's sugar-reduction ingredients, with closing expected within weeks.

Erik LindqvistNovember 16, 20265 min read2 views

A fermentation vessel linked by piping to a glass chamber of translucent protein crystals and a small berry, depicted in a clean biotech facility setting.

Amyris, Inc., the Emeryville, Calif.-based vertically integrated biomanufacturing company, said it will acquire Oobli Inc., a Davis, Calif., sweet protein innovator whose fermentation-based ingredients help food and beverage brands reduce sugar without sacrificing taste.

According to Amyris, the transaction brings together its scientific capabilities and manufacturing depth with Oobli's protein fermentation expertise. It follows the company's expansion of manufacturing capacity earlier this year at its advanced fermentation facility in Barra Bonita, Brazil, and is described by Amyris as a strategic commercial and technology expansion that accelerates its footprint in protein- and peptide-based solutions across end markets.

Amyris said the acquisition is expected to close in the coming weeks, and that all existing customer commitments and brand partnerships will continue to be honored uninterrupted as Oobli's sweet protein portfolio continues to expand as part of the Amyris business.

Strain engineering meets protein fermentation

"In Oobli, we see a commercial and technology platform that is a great complement to our own," Chief Executive Officer Kathy Fortmann said, adding that Oobli is positioned to change how sweetness reaches the market. Amyris said that combining Oobli's protein expertise with its own strain engineering, manufacturing scale and commercial capabilities could broaden its reach in food and beverage, personal care, flavor and fragrance, agriculture and other markets.

Oobli's commercial portfolio of sweet proteins is expected to be the first to benefit from the combined platform.

How the proteins are made and used

Oobli has spent the past decade refining a fermentation process to produce sweet proteins that occur naturally in rare fruits and berries found near the equator. Per the company, these proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, so they deliver sweetness without gut disruption or blood sugar spikes.

The portfolio includes three such proteins:

  • Oubli Fruit sweet protein, known scientifically as brazzein;
  • Serendipity Berry sweet protein, known scientifically as monellin;
  • Katemfe Fruit sweet protein, known scientifically as thaumatin.

The ingredients hold FDA GRAS status and are FEMA GRAS-affirmed for use as a natural flavor. Amyris said growing consumer awareness of metabolic health and the benefits of sugar reduction gives brands a new tool to cut sugar across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery.

What the two companies say

Oobli Chief Executive Officer Ali Wing said the company had long believed there was a better way to deliver the sweet taste consumers want without trade-offs to health and the environment, and that joining Amyris provides the scale and resources to pursue its ambition of making sweet proteins a global standard in sweetness solutions.

Fortmann said biomanufactured solutions succeed when they align with consumer demand and market needs, and that Oobli's platform gives brands a way to address sweet taste, sugar reduction and clean label at the same time. She added that Amyris is looking forward to welcoming the Oobli team and realizing synergies between the two platforms.